|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,913 GBX | +3.18% |
|
+6.34% | +6.93% |
| Apr. 26 | HIKMA PHARMACEUTICALS : Hikma’s Q1 progress appreciated by the markets |  |
| Apr. 25 | Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024 | CI |
Hikma Pharmaceuticals PLC reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 2,875 million compared to USD 2,517 million a year ago. Net income was USD 190 million compared to USD 188 million a year ago.
Basic earnings per share from continuing operations was USD 0.86 compared to USD 0.84 a year ago. Diluted earnings per share from continuing operations was USD 0.85 compared to USD 0.84 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +6.93% | 5.29B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
HIKMA PHARMACEUTICALS PLC 
